Epitalon Dose Conversion: Weekly to Daily Dosing Explained for Women

What Is Epitalon and Why Does the Dosing Schedule Matter?

Epitalon (also spelled epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, originally isolated from the bovine pineal gland by Vladimir Khavinson's group in St. Petersburg. Its proposed mechanism centers on stimulating telomerase activity, which may slow telomere shortening in somatic cells. Early cell-line and animal research showed telomerase induction in human fetal fibroblasts. Whether that translates to meaningful clinical benefit in adult women remains an open question.

The dosing schedule matters because Epitalon's proposed action on the pineal-hypothalamic axis is time-dependent. Circadian rhythms govern pineal melatonin release, and the timing of peptide administration relative to your own hormonal rhythm may influence outcomes. A weekly bolus and a divided daily dose deliver the same total milligrams but create very different plasma exposure curves. That distinction is clinically meaningful when the target tissue, the pineal gland, operates on a 24-hour cycle.

How the Peptide Is Typically Administered

Epitalon is not FDA-approved and has no established label. Compounding pharmacies in the United States supply it as a lyophilized powder for subcutaneous injection or, less commonly, as a nasal spray. Because there is no approved prescribing information, clinicians extrapolate doses from Khavinson's published human series and from case series circulating in longevity medicine communities. That means every dosing recommendation you read, including this one, is off-label and based on limited evidence.

Why Women Need a Different Dosing Conversation

Women's pineal function changes measurably across life stages. Melatonin amplitude declines by roughly 50% between ages 20 and 50 in women, a steeper relative drop than observed in age-matched men in some cross-sectional analyses. Estrogen modulates melatonin receptor density in the suprachiasmatic nucleus, so perimenopausal estrogen fluctuation may alter how your body responds to a pineal-targeted peptide. This is not a trivial pharmacokinetic detail. It is the reason a flat dose conversion chart written for a male-default clinical lens may not serve you well.

The Conversion Formula: Weekly to Daily Epitalon Dosing

The arithmetic is simple. The clinical judgment layered on top is not.

Daily dose (mg) = Total weekly dose (mg) ÷ 7

| Weekly Total | Daily Equivalent | Typical Use Case | |---|---|---| | 5 mg | 0.71 mg/day | Starting dose, any life stage | | 7 mg | 1.00 mg/day | Mid-titration | | 10 mg | 1.43 mg/day | Common maintenance target | | 14 mg | 2.00 mg/day | Upper range, short-course protocols only |

These figures come from Khavinson's open-label human studies, which used courses of 10 mg total delivered over 10 days (1 mg/day), or 5-day courses at 2 mg/day, in older adults. That 1999 paper is the most frequently cited primary source, though its sample sizes were small and it lacked placebo controls. No peer-reviewed RCT has established an optimal dose in women specifically.

Why You Might Choose Daily Over Weekly

A once-weekly injection gives you convenience. Daily dosing gives you steadier plasma levels. For a peptide hypothesized to reset circadian telomerase expression, steadier daily exposure aligns better with the proposed mechanism. Khavinson's protocols almost universally used consecutive daily injections rather than weekly boluses, which means the existing human data, limited as it is, was generated on daily regimens. Switching to weekly and then back-converting is a practical compromise for women who find daily injections difficult to sustain.

Why You Might Choose Weekly

Women managing menstrual cycle-related injection site sensitivity, women in postpartum recovery, or women using other injectable medications on fixed schedules may genuinely find weekly dosing easier to maintain. Adherence matters. A dose you actually take weekly beats a daily dose you abandon by week three.

Titration Protocol: Starting Low and Going Slow

Starting at the lower end of the dose range is reasonable, particularly for women who are also using hormone therapy, thyroid medications, or other peptides. The interaction data between Epitalon and exogenous estrogens or progestins is nonexistent in the published literature. That absence of data is itself a signal to proceed cautiously.

Week 1 to 2: Starting Dose

Begin at 5 mg per week, administered as either 0.71 mg daily or split into two injections of 2.5 mg. Monitor for injection site reactions and note any changes in sleep quality, since sleep is the most commonly reported subjective outcome in Khavinson's observational series.

Week 3 to 6: Uptitration Phase

If you tolerate the starting dose without significant local or systemic reactions, you may increase to 7 mg per week (1 mg/day daily equivalent). Hold at this dose for at least two weeks before moving higher. Women in perimenopause with already-disrupted sleep may notice changes in sleep architecture during this phase. Document them carefully so your clinician can assess whether they reflect a Epitalon effect or ongoing hormonal flux.

Week 7 Onward: Maintenance or Cycle End

The most commonly described protocols run for 10 to 20 days at a time, repeated two to four times per year, rather than continuous daily dosing. A 10-day course at 1 mg/day delivers 10 mg total, matching the Khavinson foundational human series. If you convert to a weekly schedule, a 10-day course becomes one full week (7 mg) plus three additional daily doses (3 mg), totaling 10 mg. That is the most straightforward way to honor the original protocol while working within a weekly injection rhythm.

Sex-Specific Physiology: How Your Hormonal Status Affects Epitalon

The following framework does not appear in Khavinson's original publications. It is derived from applying established neuroendocrine principles to Epitalon's proposed mechanism and is offered as clinical reasoning, not as tested dosing guidance.

Reproductive years (roughly ages 18 to 40): Melatonin secretion is relatively intact. The luteal phase of your menstrual cycle brings a small but measurable rise in melatonin amplitude, as documented in chronobiology research. Administering Epitalon during the follicular phase, when melatonin baseline is lower, may theoretically produce a different response than luteal-phase administration. This has not been tested.

Perimenopause (typically ages 45 to 55, highly variable): Irregular estrogen secretion disrupts suprachiasmatic nucleus signaling and flattens melatonin curves. Women in perimenopause often report worse sleep and circadian dysregulation independent of any peptide use. Separating Epitalon effects from hormonal transition symptoms will be difficult without careful symptom tracking and ideally some form of objective measurement, such as actigraphy.

Post-menopause: Melatonin amplitude is lowest in this group. Khavinson's longevity work in animals focused heavily on aging organisms with declining pineal function, so the post-menopausal woman is arguably the population closest to the studied model. The caveat is that post-menopausal women also carry the highest background rates of the conditions that require the greatest caution with unproven peptides.

PCOS: Women with PCOS show altered melatonin and cortisol rhythms compared with controls in observational data. Whether Epitalon interacts with the hyperandrogenic or insulin-resistant environment of PCOS is entirely unknown.

Pregnancy and Lactation Safety

Epitalon is not established as safe in pregnancy. Avoid it.

No controlled human studies of Epitalon in pregnancy exist. The compound has not been assigned an FDA pregnancy category because it is not FDA-approved. Animal reproductive toxicology data are not available in the peer-reviewed literature to a degree that would allow any meaningful safety conclusion.

The mechanism of action itself raises a theoretical concern. Telomerase stimulation in a developing fetus involves different cellular contexts than in adult somatic cells. Trophoblast invasion and placental development are already telomerase-active processes, as described in placental biology research. Introducing an exogenous telomerase-stimulating peptide during this period is an unquantifiable risk.

If you are trying to conceive, discuss stopping Epitalon at least one full menstrual cycle before attempting conception. Use reliable contraception while on Epitalon if pregnancy is not your current goal. If you discover you are pregnant while using Epitalon, stop immediately and contact your clinician.

Lactation

No data exist on Epitalon transfer into human breast milk. Given its peptide structure (molecular weight approximately 390 Da), small peptides can transfer into breast milk to varying degrees. Without pharmacokinetic data in lactating women, the safe and conservative position is to avoid Epitalon while breastfeeding.

Contraception Requirement

Because Epitalon lacks any reproductive safety data, women of reproductive potential using this compound should use reliable contraception throughout the course and for at least one full cycle after the last dose.

Who This Is Right For, and Who Should Not Use It

This section is framed by life stage and existing condition, because those factors change the benefit-to-uncertainty ratio substantially.

Potentially Appropriate Candidates

Women who may reasonably consider Epitalon under clinician supervision include post-menopausal women exploring longevity protocols who understand the evidence is preliminary, perimenopausal women with documented circadian disruption who have exhausted better-evidenced interventions, and women in their reproductive years using it strictly off-label for anti-aging purposes with strong contraception in place and clear informed consent about the evidence gap.

Women Who Should Not Use Epitalon

Women who are pregnant or trying to conceive should not use Epitalon. Women who are breastfeeding should not use it. Women with a personal or family history of hematologic malignancies should exercise significant caution: telomerase activation is a known feature of cancer cell biology, as detailed in oncology literature, and stimulating telomerase in someone with underlying pre-malignant cells is a theoretical risk that no current trial has addressed.

Women on melatonin receptor agonists (ramelteon, tasimelteon) may find additive effects at the pineal level. That interaction has not been studied.

Practical Injection and Reconstitution Guide for Women

Compounded Epitalon typically arrives as a lyophilized powder in 5 mg or 10 mg vials. Reconstitute with bacteriostatic water, using 1 mL of bacteriostatic water per 5 mg of peptide to yield a concentration of 5 mg/mL (5,000 mcg/mL). At that concentration:

• 0.71 mg/day = 0.14 mL per injection
• 1.0 mg/day = 0.2 mL per injection
• 1.43 mg/day = 0.286 mL per injection

Use a 29-gauge or 31-gauge insulin syringe. Rotate injection sites across the abdomen or lateral thigh. Women in the perimenstrual phase often report increased injection site sensitivity, which is consistent with known estrogen and progesterone effects on mast cell activity and skin sensitivity. Shifting to thigh injections during days 25 to 2 of your cycle is a practical workaround some women find helpful.

Store reconstituted vials refrigerated at 2 to 8 degrees Celsius and use within 28 days. Discard if the solution becomes cloudy.

Evidence Quality: What We Actually Know vs. What Is Extrapolated

Women have been systematically under-represented in peptide longevity research. Khavinson's published human studies from the 1990s and early 2000s included mixed-sex cohorts of older adults, but sex-disaggregated data were not consistently reported. The trials were not blinded, did not use placebo controls, and were conducted largely outside the regulatory trial framework that produces the level of evidence required for FDA approval.

A 2003 paper in Annals of the New York Academy of Sciences summarized Khavinson's broader work and reported reductions in biological aging markers and mortality rates in treated cohorts, but the methodology was observational. The most direct human endpoint data come from a study showing statistically significant telomere lengthening in cultured cells after Epitalon exposure. That is a cell-culture result, not a clinical outcome in a living woman.

A 2016 review in Current Aging Science catalogued Epitalon's animal data, including lifespan extension in mice and melatonin normalization in aging rats, and noted that human translation remains unconfirmed. The review authors called explicitly for randomized controlled trials. Those trials have not materialized.

The honest summary: the theoretical rationale is biologically interesting, the animal data are suggestive, and the human data are too thin and too methodologically limited to make confident efficacy claims. Women using Epitalon are doing so on the basis of plausible mechanism and early-stage science, not proven clinical benefit.

Monitoring While on Epitalon

No validated monitoring protocol exists. The following is a practical framework based on the compound's proposed mechanism and the populations most likely to use it.

Before starting: Complete blood count, comprehensive metabolic panel, and, for women over 40, fasting insulin and hemoglobin A1c. These establish a baseline for metabolic parameters and flag any pre-existing conditions that might affect risk-benefit assessment.

At 4 weeks: Subjective sleep quality assessment using a validated instrument such as the Pittsburgh Sleep Quality Index. Objective tracking with a consumer actigraphy device (Oura, Fitbit, Apple Watch) gives you data your clinician can actually interpret.

At 8 to 12 weeks or end of course: Repeat CBC if you had any baseline abnormalities. Review symptom log. Assess whether any observed change is plausibly attributable to Epitalon or more likely explained by concurrent interventions, seasonal changes, or hormonal cycle variation.

Women on hormone therapy: Discuss Epitalon use explicitly with the clinician managing your HRT. There are no known pharmacokinetic interactions, but the absence of interaction data is not the same as confirmed safety.

Frequently Asked Questions